Affinivax
Biotechnology company that developed next-generation vaccines using proprietary MAPS (Multiple Antigen Presenting System) technology. Acquired by GSK in 2022 for $3.3 billion.
Location
Cambridge, Massachusetts, USA
Founded
2014
Categories
biotech, vaccines, infectious-disease, acquired
